The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance

Current Opinion in Virology

Volumn 2, Issue 5, 2012, Pages 644-650

  Götte, Matthias ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; CHEMICAL REACTION; GENE MUTATION; GENE REPLICATION; GENETIC ANALYSIS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; THERMODYNAMICS;

EID: 84867398802     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.08.004     Document Type: Review

References (51)

1. M.A. Thompson, J.A. Aberg, J.F. Hoy, A. Telenti, C. Benson, P. Cahn, J.J. Eron, H.F. Gunthard, S.M. Hammer, and P. Reiss Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society-USA panel JAMA: The Journal of the American Medical Association 308 2012 387 402
2. V.A. Johnson, V. Calvez, H.F. Gunthard, R. Paredes, D. Pillay, R. Shafer, A.M. Wensing, and D.D. Richman 2011 update of the drug resistance mutations in HIV-1 Topics in Antiviral Medicine 19 2011 156 164
3. C. Welsch, A. Jesudian, S. Zeuzem, and I. Jacobson New direct-acting antiviral agents for the treatment of hepatitis c virus infection and perspectives Gut 61 Suppl 1 2012 36 46
4. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis c virus Science Translational Medicine 2 2010 30ra32
5. J.H. Condra Resistance to HIV protease inhibitors Haemophilia: The Official Journal of the World Federation of Hemophilia 4 1998 610 615
6. A.D. Luber Genetic barriers to resistance and impact on clinical response MedGenMed: Medscape General Medicine 7 2005 69
7. Z. Zhang, R. Hamatake, and Z. Hong Clinical utility of current nnrtis and perspectives of new agents in this class under development Antiviral Chemistry & Chemotherapy 15 2004 121 134
8. D.J. Kempf, J.D. Isaacson, M.S. King, S.C. Brun, Y. Xu, K. Real, B.M. Bernstein, A.J. Japour, E. Sun, and R.A. Rode Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients Journal of Virology 75 2001 7462 7469
9. H. Mo, M.S. King, K. King, A. Molla, S. Brun, and D.J. Kempf Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates Journal of Virology 79 2005 3329 3338
10. M.W. Tang, and R.W. Shafer Hiv-1 antiretroviral resistance: scientific principles and clinical applications Drugs 72 2012 e1 e25
11. N. Beerenwinkel, M. Daumer, T. Sing, J. Rahnenfuhrer, T. Lengauer, J. Selbig, D. Hoffmann, and R. Kaiser Estimating HIV evolutionary pathways and the genetic barrier to drug resistance The Journal of Infectious Diseases 191 2005 1953 1960
12. K.J. Metzner, P. Rauch, V. von Wyl, C. Leemann, C. Grube, H. Kuster, J. Boni, R. Weber, and H.F. Gunthard Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy The Journal of Infectious Diseases 201 2010 1063 1071
13. A.M. Wensing, N.M. van Maarseveen, and M. Nijhuis Fifteen years of HIV protease inhibitors: raising the barrier to resistance Antiviral Research 85 2010 59 74
14. K. Theys, K. Deforche, G. Beheydt, Y. Moreau, K. van Laethem, P. Lemey, R.J. Camacho, S.Y. Rhee, R.W. Shafer, E. Van Wijngaerden, and A.M. Vandamme Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape BMC Bioinformatics 11 2010 409
15. D.A. van de Vijver, A.M. Wensing, G. Angarano, B. Asjo, C. Balotta, E. Boeri, R. Camacho, M.L. Chaix, D. Costagliola, and A. De Luca The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes Journal of Acquired Immune Deficiency Syndromes 41 2006 352 360
16. D.R. Kuritzkes Preventing and managing resistance in the clinical setting Journal of Acquired Immune Deficiency Syndromes 34 Suppl 2 2003 S103 S110
17. R. Gish, J.D. Jia, S. Locarnini, and F. Zoulim Selection of chronic hepatitis b therapy with high barrier to resistance The Lancet Infectious Diseases 12 2012 341 353
18. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis c virus Hepatology 53 2011 1742 1751
19. M.H. Powdrill, E.P. Tchesnokov, R.A. Kozak, R.S. Russell, R. Martin, E.S. Svarovskaia, H. Mo, R.D. Kouyos, and M. Gotte Contribution of a mutational bias in hepatitis c virus replication to the genetic barrier in the development of drug resistance Proceedings of the National Academy of Sciences of the United States of America 108 2011 20509 20513
20. V. Cento, C. Mirabelli, R. Salpini, S. Dimonte, A. Artese, G. Costa, F. Mercurio, V. Svicher, L. Parrotta, and A. Bertoli Hcv genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors PLoS ONE 7 2012 e39652
21. L. Delang, I. Vliegen, M. Froeyen, and J. Neyts Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis c virus replication Antimicrobial Agents and Chemotherapy 55 2011 4103 4113
22. J.D. Roberts, K. Bebenek, and T.A. Kunkel The accuracy of reverse transcriptase from HIV-1 Science 242 1988 1171 1173
23. B.D. Preston, B.J. Poiesz, and L.A. Loeb Fidelity of HIV-1 reverse transcriptase Science 242 1988 1168 1171
24. W.M. Kati, K.A. Johnson, L.F. Jerva, and K.S. Anderson Mechanism and fidelity of HIV reverse transcriptase The Journal of Biological Chemistry 267 1992 25988 25997
25. S.G. Kerr, and K.S. Anderson RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates Biochemistry 36 1997 14056 14063
26. T. Matamoros, B. Kim, and L. Menendez-Arias Mechanistic insights into the role of val75 of HIV-1 reverse transcriptase in misinsertion and mispair extension fidelity of DNA synthesis Journal of Molecular Biology 375 2008 1234 1248
27. R.S. Harris, and M.T. Liddament Retroviral restriction by apobec proteins Nature Reviews. Immunology 4 2004 868 877
28. R. Schuurman, M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S.A. Danner, J. Mulder, C. Loveday, and C. Christopherson Rapid changes in human immunodeficiency virus type 1 rna load and appearance of drug-resistant virus populations in persons treated with lamivudine (3tc) The Journal of Infectious Diseases 171 1995 1411 1419
29. W. Keulen, N.K. Back, A. van Wijk, C.A. Boucher, and B. Berkhout Initial appearance of the 184ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase Journal of Virology 71 1997 3346 3350
30. S.D. Frost, M. Nijhuis, R. Schuurman, C.A. Boucher, and A.J. Brown Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection Journal of Virology 74 2000 6262 6268
31. L.C. Mulder, A. Harari, and V. Simon Cytidine deamination induced HIV-1 drug resistance Proceedings of the National Academy of Sciences of the United States of America 105 2008 5501 5506
32. P. Jern, R.A. Russell, V.K. Pathak, and J.M. Coffin Likely role of apobec3g-mediated g-to-a mutations in HIV-1 evolution and drug resistance PLoS Pathogens 5 2009 e1000367
33. S. Fourati, I. Malet, M. Binka, S. Boukobza, M. Wirden, S. Sayon, A. Simon, C. Katlama, V. Simon, V. Calvez, and A.G. Marcelin Partially active HIV-1 vif alleles facilitate viral escape from specific antiretrovirals AIDS 24 2010 2313 2321
34. H.A. Sadler, M.D. Stenglein, R.S. Harris, and L.M. Mansky Apobec3g contributes to HIV-1 variation through sublethal mutagenesis Journal of Virology 84 2010 7396 7404
35. A. De Luca The impact of resistance on viral fitness and its clinical implications A.M. Geretti, Antiretroviral Resistance in Clinical Practice 2006 Mediscript London
36. N.K. Back, M. Nijhuis, W. Keulen, C.A. Boucher, B.O. Oude Essink, A.B. van Kuilenburg, A.H. van Gennip, and B. Berkhout Reduced replication of 3tc-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme The EMBO Journal 15 1996 4040 4049
37. J.M. Pawlotsky, I. Najera, and I. Jacobson Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent rna polymerase Antiviral Therapy 17 2012 411 423
38. S. Ali, V. Leveque, S. Le Pogam, H. Ma, F. Philipp, N. Inocencio, M. Smith, A. Alker, H. Kang, and I. Najera Selected replicon variants with low-level in vitro resistance to the hepatitis c virus ns5b polymerase inhibitor psi-6130 lack cross-resistance with r1479 Antimicrobial Agents and Chemotherapy 52 2008 4356 4369
39. H. Dutartre, C. Bussetta, J. Boretto, and B. Canard General catalytic deficiency of hepatitis c virus rna polymerase with an s282t mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues Antimicrobial Agents and Chemotherapy 50 2006 4161 4169
40. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.H. Sun, and D.R. O'Boyle 2nd Chemical genetics strategy identifies an hcv ns5a inhibitor with a potent clinical effect Nature 465 2010 96 100
41. R.A. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis c virus ns5a inhibitor bms-790052 in an in vitro replicon system Antimicrobial Agents and Chemotherapy 54 2010 3641 3650
42. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, R. Kauffman, L. McNair, J. Alam, and A.J. Muir Telaprevir with peginterferon and ribavirin for chronic hcv genotype 1 infection The New England Journal of Medicine 360 2009 1827 1838
43. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J.P. Bronowicki, M. Bourliere, S. Gharakhanian, and L. Bengtsson Telaprevir and peginterferon with or without ribavirin for chronic hcv infection The New England Journal of Medicine 360 2009 1839 1850
44. B. Brenner, D. Turner, M. Oliveira, D. Moisi, M. Detorio, M. Carobene, R.G. Marlink, J. Schapiro, M. Roger, and M.A. Wainberg A v106m mutation in HIV-1 clade c viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors AIDS 17 2003 F1 F5
45. A. Piralla, S. Paolucci, R. Gulminetti, G. Comolli, and F. Baldanti Hiv integrase variability and genetic barrier in antiretroviral naive and experienced patients Virology Journal 8 2011 149
46. M.A. Wainberg, and B.G. Brenner The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs Molecular Biology International 2012 2012 256982
47. V. Svicher, V. Cento, R. Salpini, F. Mercurio, M. Fraune, B. Beggel, Y. Han, C. Gori, L. Wittkop, and A. Bertoli Role of hepatitis b virus genetic barrier in drug-resistance and immune-escape development Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 43 2011 975 983
48. D. Coutsinos, C.F. Invernizzi, H. Xu, D. Moisi, M. Oliveira, B.G. Brenner, and M.A. Wainberg Template usage is responsible for the preferential acquisition of the k65r reverse transcriptase mutation in subtype c variants of human immunodeficiency virus type 1 Journal of Virology 83 2009 2029 2033
49. H. Sunpath, B. Wu, M. Gordon, J. Hampton, B. Johnson, M.Y. Moosa, C. Ordonez, D.R. Kuritzkes, and V.C. Marconi High rate of k65r for antiretroviral therapy-naive patients with subtype c HIV infection failing a tenofovir-containing first-line regimen AIDS 26 2012 1679 1684
50. D. Coutsinos, C.F. Invernizzi, D. Moisi, M. Oliveira, J.L. Martinez-Cajas, B.G. Brenner, and M.A. Wainberg A template-dependent dislocation mechanism potentiates k65r reverse transcriptase mutation development in subtype c variants of HIV-1 PLoS ONE 6 2011 e20208
51. G. Quarta, K. Sin, and T. Schlick Dynamic energy landscapes of riboswitches help interpret conformational rearrangements and function PLoS Computational Biology 8 2012 e1002368